|
Indications And Usage Tri-Sprintec ® (Norgestimate And Ethinyl Estradiol Tablets Usp) Is Indicated For The Prevention Of Pregnancy In Women Who Elect To Use Oral Contraceptives As A Method Of Contraception. Tri-Sprintec (Norgestimate And Ethinyl Estradiol Tablets Usp) Is Indicated For The Treatment Of Moderate Acne Vulgaris In Females At Least 15 Years Of Age, Who Have No Known Contraindications To Oral Contraceptive Therapy And Have Achieved Menarche. Tri-Sprintec (Norgestimate And Ethinyl Estradiol Tablets Usp) Should Be Used For The Treatment Of Acne Only If The Patient Desires An Oral Contraceptive For Birth Control. Oral Contraceptives Are Highly Effective For Pregnancy Prevention. Table 2 Lists The Typical Accidental Pregnancy Rates For Users Of Combination Oral Contraceptives And Other Methods Of Contraception. The Efficacy Of These Contraceptive Methods, Except Sterilization, The Iud, And The Norplant ® System, Depends Upon The Reliability With Which They Are Used. Correct And Consistent Use Of Methods Can Result In Lower Failure Rates. Table 2: Percentage Of Women Experiencing An Unintended Pregnancy During The First Year Of Typical Use And The First Year Of Perfect Use Of Contraception And The Percentage Continuing Use At The End Of The First Year. United States. % Of Women Experiencing An Unintended Pregnancy Within The First Year Of Use % Of Women Continuing Use At One Year Among Couples Attempting To Avoid Pregnancy, The Percentage Who Continue To Use A Method For One Year. Method Typical Use Among Typical Couples Who Initiate Use Of A Method (Not Necessarily For The First Time), The Percentage Who Experience An Accidental Pregnancy During The First Year If They Do Not Stop Use For Any Other Reason. Perfect Use Among Couples Who Initiate Use Of A Method (Not Necessarily For The First Time) And Who Use It Perfectly (Both Consistently And Correctly), The Percentage Who Experience An Accidental Pregnancy During The First Year If They Do Not Stop Use For Any Other Reason. (1) (2) (3) (4) Chance The Percents Becoming Pregnant In Columns (2) And (3) Are Based On Data From Populations Where Contraception Is Not Used And From Women Who Cease Using Contraception In Order To Become Pregnant. Among Such Populations, About 89% Become Pregnant Within One Year. This Estimate Was Lowered Slightly (To 85%) To Represent The Percent Who Would Become Pregnant Within One Year Among Women Now Relying On Reversible Methods Of Contraception If They Abandoned Contraception Altogether. 85 85 Spermicides Foams, Creams, Gels, Vaginal Suppositories, And Vaginal Film. 26 6 40 Periodic Abstinence 25 63 Calendar 9 Ovulation Method 3 Sympto-Thermal Cervical Mucus (Ovulation) Method Supplemented By Calendar In The Pre-Ovulatory And Basal Body Temperature In The Post-Ovulatory Phases. 2 Post-Ovulation 1 Cap With Spermicidal Cream Or Jelly. Parous Women 40 26 42 Nulliparous Women 20 9 56 Sponge Parous Women 40 20 42 Nulliparous Women 20 9 56 Diaphragm 20 6 56 Withdrawal 19 4 Condom Without Spermicides. Female (Reality ® ) 21 5 56 Male 14 3 61 Pill 5 71 Progestin Only 0.5 Combined 0.1 Iud Progesterone T 2 1.5 81 Copper T380a 0.8 0.6 78 Lng 20 0.1 0.1 81 Depo-Provera ® 0.3 0.3 70 Norplant ® And Norplant-2 ® 0.05 0.05 88 Female Sterilization 0.5 0.5 100 Male Sterilization 0.15 0.10 100 Hatcher Et Al., 1998 Ref. #1. Emergency Contraceptive Pills: Treatment Initiated Within 72 Hours After Unprotected Intercourse Reduces The Risk Of Pregnancy By At Least 75%. The Treatment Schedule Is One Dose Within 72 Hours After Unprotected Intercourse, And A Second Dose 12 Hours After The First Dose. The Food And Drug Administration Has Declared The Following Brands Of Oral Contraceptives To Be Safe And Effective For Emergency Contraception: Ovral ® (1 Dose Is 2 White Pills), Alesse ® (1 Dose Is 5 Pink Pills), Nordette ® Or Levlen ® (1 Dose Is 2 Light-Orange Pills), Lo/ovral ® (1 Dose Is 4 White Pills), Triphasil ® Or Tri-Levlen ® (1 Dose Is 4 Yellow Pills). Lactational Amenorrhea Method: Lam Is A Highly Effective, Temporary Method Of Contraception. However, To Maintain Effective Protection Against Pregnancy, Another Method Of Contraception Must Be Used As Soon As Menstruation Resumes, The Frequency Or Duration Of Breastfeeds Is Reduced, Bottle Feeds Are Introduced, Or The Baby Reaches Six Months Of Age. Source: Trussell J, Contraceptive Efficacy. In Hatcher Ra, Trussell J, Stewart F, Cates W, Stewart Gk, Kowal D, Guest F, Contraceptive Technology: Seventeenth Revised Edition. New York Ny: Irvington Publishers, 1998. Tri-Sprintec (Norgestimate And Ethinyl Estradiol Tablets Usp) Has Not Been Studied For And Is Not Indicated For Use In Emergency Contraception. In Four Clinical Trials With Tri-Sprintec (Norgestimate And Ethinyl Estradiol Tablets Usp), A Total Of 4,756 Subjects Completed 45,244 Cycles, And The Use-Efficacy Pregnancy Rate Was Approximately 1 Pregnancy Per 100 Women-Years. Tri-Sprintec (Norgestimate And Ethinyl Estradiol Tablets Usp) Was Evaluated For The Treatment Of Acne Vulgaris In Two Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Six (28 Day) Cycle Studies. 221 Patients Received Tri-Sprintec (Norgestimate And Ethinyl Estradiol Tablets Usp) And 234 Patients Received Placebo. Mean Age At Enrollment For Both Groups Was 28 Years. At The End Of 6 Months, The Mean Total Lesion Count Changes From 55 To 31 (42% Reduction) In Patients Treated With Tri-Sprintec (Norgestimate And Ethinyl Estradiol Tablets Usp) And From 54 To 38 (27% Reduction) In Patients Similarly Treated With Placebo. Table 3 Summarizes The Changes In Lesion Count For Each Type Of Lesion In The Itt Population. Based On The Investigator’s Global Assessment Conducted At The Final Visit, Patients Treated With Tri-Sprintec (Norgestimate And Ethinyl Estradiol Tablets Usp) Showed A Statistically Significant Improvement In Total Lesions Compared To Those Treated With Placebo. Table 3: Acne Vulgaris Indication. Combined Results: Two Multicenter, Placebo-Controlled Trials. Observed Means At Six Months (Locf) Locf: Last Observation Carried Forward And At Baseline. Intent To Treat Population. Tri-Sprintec (N = 221) Placebo (N = 234) Difference In Counts Between Tri-Sprintec And Placebo At 6 Months # Of Lesions Counts % Reduction Counts % Reduction Inflammatory Lesions Baseline Mean 19 19 Sixth Month Mean 10 48% 13 30% 3 (95% Ci: -1.2, 5.1) Non-Inflammatory Lesions Baseline Mean 36 35 Sixth Month Mean 22 34% 25 21% 3 (95% Ci: -0.2, 7.8) Total Lesions Baseline Mean 55 54 Sixth Month Mean 31 42% 38 27% 7 (95% Ci: 2, 11.9)
|